The efficacy of Abound on anastomotic leakage after esophagectomy

A phase II trial to evaluate the efficacy of Abound (nutrition product including HMB, arginine, and glutamine) on the clinical course of anastomotic leakage after esophagectomy

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCTs041190018

Enrollment

Registered

2019-04-11

Start date

2019-08-27

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anastomotic leakage after esophagectomy Esophageal cancer

Interventions

Administration of Abound

Abound

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Age <= 20 years 2) Performance status (PS) 0-2 3) Patients who underwent esophagectomy for esophageal cancer 4) Patients who were diagnosed as an anastomotic leakage within 14 days after esophagectomy 5) Written informed consent

Exclusion criteria

Exclusion criteria: 1) Severe pneumonia and sepsis 2) Leakage at the closed stump of duodenum and jejunum 3) Repeated surgery 4) Patients requiring a limiting of the water amount 5) Patients incompatible to Abound 6) Pregnancy 7) Ineligible for the study at the physician's assessment

Design outcomes

Primary

Measure	Time frame
The period from the diagnosis to cure of the anastomotic leakage	—

Secondary

Measure	Time frame
Total amount and safety of Abound administration, duration of drain placement and fasting, hospital stay, location and procedure of anastomosis, blood test and nutritional management	—

Contacts

Public ContactMitsuro Kanda

Nagoya University Graduate School of Medicine

m-kanda@med.nagoya-u.ac.jp+81-52-744-2249

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026